Öz
Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. With this use and longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to anti-TNF agents. Since these drugs are often prescribed to severe rheumatologic patients, there is a controversy about whether the autoimmune diseases that could be related to underlying disease or anti-TNF therapy. We aimed to discuss this subject under the light of literature.
Anahtar Kelimeler
Anti-TNF therapy autoimmune diseases vasculitis systemic lupus erythematosus
Kaynakça
- Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86(4):242-51.
- Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143-7.
- Font J, Cervera R, Ramos-Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004;33:217-30.
- Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents A double-edged sword? Autoimmun Rev 2010;9(3):188-93.
- Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol 2008;26 (Suppl. 49):S23-9.
- Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc 2012;87(8):739-45.
- Jani M, Dixon WG, Kersley-Fleet L et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open 2017;3:e000314. doi:10.1136/rmdopen-2016000314.
Öz
Anti-TNF tedavilerin romatolojik ve otoimmün hastalıkların tedavisinde yaygın kullanımı ve uzun dönem takipleri ile birlikte, paradoksal olarak anti-TNF ilişkili otoimmün hastalıklarla ilgili artan sayıda bildiriler olmaktadır. Bu ilaçlar genelde ağır hastalık aktivitesi olan romatolojik hastalarda kullanıldığından, bazı durumlarda bu gelişen hastalıkların altta yatan hastalığa da bağlı olabilmesi ile ilgili çelişkiler bulunmaktadır. Giderek artan vaka serilerinden elde edilen bilgiler ışığında bu konuyu tartışmayı amaçladık
Anahtar Kelimeler
Anti-TNF tedavi otoimmün hastalık vaskülit sistemik lupus eritematoz
Kaynakça
- Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86(4):242-51.
- Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143-7.
- Font J, Cervera R, Ramos-Casals M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum 2004;33:217-30.
- Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents A double-edged sword? Autoimmun Rev 2010;9(3):188-93.
- Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol 2008;26 (Suppl. 49):S23-9.
- Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc 2012;87(8):739-45.
- Jani M, Dixon WG, Kersley-Fleet L et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open 2017;3:e000314. doi:10.1136/rmdopen-2016000314.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Ek |
| Yazarlar | |
| Yayımlanma Tarihi | 25 Ekim 2019 |
| Gönderilme Tarihi | 19 Ekim 2018 |
| Yayımlandığı Sayı | Yıl 2019 |